JPWO2020205632A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020205632A5 JPWO2020205632A5 JP2021557941A JP2021557941A JPWO2020205632A5 JP WO2020205632 A5 JPWO2020205632 A5 JP WO2020205632A5 JP 2021557941 A JP2021557941 A JP 2021557941A JP 2021557941 A JP2021557941 A JP 2021557941A JP WO2020205632 A5 JPWO2020205632 A5 JP WO2020205632A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- mutations
- exon
- poziotinib
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962826758P | 2019-03-29 | 2019-03-29 | |
| US62/826,758 | 2019-03-29 | ||
| PCT/US2020/025478 WO2020205632A1 (fr) | 2019-03-29 | 2020-03-27 | Composés ayant une activité antitumorale contre des cellules cancéreuses portant des insertions her2 exon 21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022527499A JP2022527499A (ja) | 2022-06-02 |
| JPWO2020205632A5 true JPWO2020205632A5 (fr) | 2023-03-30 |
Family
ID=72666271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557941A Pending JP2022527499A (ja) | 2019-03-29 | 2020-03-27 | Ｈｅｒ２エクソン２１挿入を有するがん細胞に対する抗腫瘍活性を有する化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220175778A1 (fr) |
| EP (1) | EP3946632A4 (fr) |
| JP (1) | JP2022527499A (fr) |
| KR (1) | KR20210145161A (fr) |
| CN (1) | CN113766955A (fr) |
| AU (1) | AU2020256119A1 (fr) |
| BR (1) | BR112021019376A2 (fr) |
| CA (1) | CA3132834A1 (fr) |
| IL (1) | IL286576A (fr) |
| MX (1) | MX2021011925A (fr) |
| SG (1) | SG11202109531UA (fr) |
| WO (1) | WO2020205632A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020214824A1 (fr) * | 2019-04-17 | 2020-10-22 | Board Of Regents, The University Of Texas System | Composés contre le cancer portant des mutations egfr résistantes aux inhibiteurs de la tyrosine kinase |
| UY39593A (es) * | 2020-12-29 | 2022-07-29 | Spectrum Pharmaceuticals Inc | Tratamiento para tumores sólidos malignos |
| WO2024036234A1 (fr) * | 2022-08-09 | 2024-02-15 | Heligenics Inc. | Procédé d'évaluation de la pertinence clinique d'une variance génétique |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101317809B1 (ko) * | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
| KR102355121B1 (ko) * | 2011-12-14 | 2022-02-09 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 암 요법을 위한 병립 유전자 비활성화 생물표식과 표적들 |
| EP3463462A4 (fr) * | 2016-05-31 | 2020-07-29 | Société des Produits Nestlé S.A. | Procédés de sélection de pharmacothérapie pour des patients atteints de cancer du sein sur la base du sous-typage des voies her2 et her3 |
| CN110291104B (zh) * | 2016-11-17 | 2023-11-03 | 得克萨斯州大学系统董事会 | 具有针对携带egfr或her2外显子20突变之癌细胞的抗肿瘤活性的化合物 |
| KR20210107023A (ko) * | 2018-12-21 | 2021-08-31 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 암 치료를 위한 조합 요법 |
-
2020
- 2020-03-27 CN CN202080032340.6A patent/CN113766955A/zh active Pending
- 2020-03-27 SG SG11202109531UA patent/SG11202109531UA/en unknown
- 2020-03-27 KR KR1020217032121A patent/KR20210145161A/ko unknown
- 2020-03-27 WO PCT/US2020/025478 patent/WO2020205632A1/fr unknown
- 2020-03-27 BR BR112021019376A patent/BR112021019376A2/pt not_active Application Discontinuation
- 2020-03-27 CA CA3132834A patent/CA3132834A1/fr active Pending
- 2020-03-27 AU AU2020256119A patent/AU2020256119A1/en active Pending
- 2020-03-27 US US17/600,017 patent/US20220175778A1/en active Pending
- 2020-03-27 MX MX2021011925A patent/MX2021011925A/es unknown
- 2020-03-27 EP EP20782979.7A patent/EP3946632A4/fr active Pending
- 2020-03-27 JP JP2021557941A patent/JP2022527499A/ja active Pending
-
2021
- 2021-09-22 IL IL286576A patent/IL286576A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502059A5 (fr) | ||
| US11291667B2 (en) | Combination therapy involving diaryl macrocyclic compounds | |
| JP2023174661A5 (fr) | ||
| JP2014097929A5 (fr) | ||
| TWI762784B (zh) | Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途 | |
| JP7372253B2 (ja) | 癌の治療における使用のためのチューブリン重合阻害剤とポリ（ａｄｐ－リボース）ポリメラーゼ（ｐａｒｐ）阻害剤との新規組合せ | |
| CN110730663A (zh) | 阿帕替尼和c-Met抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| RU2020134932A (ru) | Соединения с противоопухолевой активностью против раковых клеток, несущих мутации в экзоне 19her2 | |
| CN111184863A (zh) | 酪氨酸激酶抑制剂、cdk4/6抑制剂、serd联合在制备治疗肿瘤的药物中的用途 | |
| WO2020239051A1 (fr) | Utilisations d'un inhibiteur de cdk4/6 conjointement avec un inhibiteur de vegfr dans la préparation d'un médicament pour le traitement d'une tumeur | |
| JPWO2020205632A5 (fr) | ||
| Pan et al. | Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non‐small cell lung cancer | |
| WO2024088275A1 (fr) | Utilisation d'un composé naphtylamide dans le traitement de tumeurs résistantes aux médicaments | |
| Jeon et al. | Combination of dabrafenib and trametinib in patients with metastatic BRAFV600E-mutated thyroid cancer | |
| Bo et al. | Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1* 28 and UGT1A1* 6 polymorphisms | |
| JPWO2020205521A5 (fr) | ||
| JPWO2020214831A5 (fr) | ||
| WO2021023204A1 (fr) | Utilisation d'un inhibiteur de cdk4/6 en combinaison avec un inhibiteur de tyrosine kinase multi-cible dans la préparation d'un médicament pour le traitement d'une tumeur | |
| JP7430890B2 (ja) | 置換ブテンアミドの応用 | |
| JPWO2020214824A5 (fr) | ||
| JPWO2020132633A5 (fr) | ||
| Yansong et al. | The preliminary report about the efficacy and safety evaluation of apatinib in progressive radioactive iodine-refractory differentiated thyroid cancer within 8 weeks | |
| JPWO2019191279A5 (fr) | ||
| CN115397415A (zh) | 乳腺癌治疗剂 | |
| US20130005747A1 (en) | Method for selecting a cancer therapy |